Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $6.58, but opened at $6.79. Coloplast A/S shares last traded at $6.8140, with a volume of 15,818 shares changing hands.
Analyst Ratings Changes
Separately, Kepler Capital Markets raised Coloplast A/S to a “strong-buy” rating in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold”.
Get Our Latest Research Report on Coloplast A/S
Coloplast A/S Trading Up 3.0%
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last announced its quarterly earnings results on Tuesday, August 18th. The company reported $0.10 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.10. Coloplast A/S had a return on equity of 33.15% and a net margin of 7.46%. On average, sell-side analysts expect that Coloplast A/S Sponsored ADR will post 0.38 earnings per share for the current year.
About Coloplast A/S
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
Featured Stories
- Five stocks we like better than Coloplast A/S
- Home Depot Analysts See a Path to $375 and Beyond
- RTX Stock Gets a Radar Lock on a $23B Navy Win
- Berkshire Just Made a Huge Alphabet Bet—Should You Follow?
- Michael Burry Is Betting Against Palantir Again—Should Investors Care?
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
